Business Context and Reporting Period
Palisade Bio, Inc. (PALI) filed a Form 8-K on March 27, 2026, reporting a strategic transaction to support its clinical development program. The company is preparing for a Phase 2 study of PALI-2108 for the treatment of moderate to severe Ulcerative Colitis (UC).
Key Financial Metrics and Transaction Details
The filing details a private placement transaction executed on March 27, 2026:
- Shares Issued: 1,536,885 shares of Common Stock.
- Total Proceeds: $3.0 million.
- Price Per Share: $1.952 (based on the average closing price for the five trading days prior to the closing date).
- Investor: An affiliate of Iterative Scopes, Inc. d/b/a Iterative Health (IH).
- Regulatory Status: Transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity positions for the reporting period.
Material Changes and Strategic Agreements
Concurrent with the equity issuance, the Company entered into a Master Services Agreement (MSA) with Iterative Health, effective March 30, 2026. Under this agreement, Iterative Health will assist Palisade Bio with patient enrollment for the upcoming Phase 2 UC study to expedite the process.
Guidance, Outlook, and Risks
Management's outlook focuses on the initiation of the Phase 2 clinical study for PALI-2108. The filing includes standard forward-looking statements regarding the Company's intentions and expectations for the study and patient enrollment. These statements are subject to risks and uncertainties, including those outlined in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Verify the impact of the $3.0 million capital raise on the Company's cash runway and ability to fund the Phase 2 UC study.
- Review the specific terms of the Master Services Agreement with Iterative Health regarding enrollment targets and costs.
- Assess the dilution impact of issuing 1,536,885 shares to an affiliate of a service provider.
- Confirm the timeline for the commencement of the Phase 2 study as referenced in the forward-looking statements.